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Galactose levels are determined by dietary sources (primarily
lactose) and metabolism-related factors. The theory linking galac-
tose to ovarian cancer aetiology originates from galactosaemia,
which is characterized by the absence of transferase. Some galac-
tosaemics experience ovarian failure or have elevated
gonadotropins levels (Kaufman et al, 1981), which may increase
ovarian cancer risk (Gardner, 1961; Cramer and Welch, 1983). An
increased ovarian cancer risk has been reported with higher lactose
intakes and with a higher lactose to transferase activity ratio
(Cramer et al, 1989).
The surgical diagnosis of benign epithelial tumours declines at
ages when epithelial ovarian cancer incidence increases,
suggesting that a small proportion of BOTs may progress to their
invasive malignant counterparts (Bennington et al, 1968). This is
consistent with observations of benign neoplasia located adjacent
to or within ovarian cancers (McKay, 1962; Puls et al, 1992), and
of benign to malignant epithelium histologic transition in one-
quarter of a sample of ovarian cancers (Puls et al, 1992). Thus,
benign and malignant ovarian tumours may share a common aeti-
ology, and if so, they afford an opportunity to investigate potential
risk factors closer to the time of aetiologic interest.
MATERIALS AND METHODS
Methods of this study have been described in more detail else-
where (Westhoff et al, 2000). In this study English-speaking
women, aged 18 to 74, with a telephone, residing in the New York
metropolitan area within 50 miles of a participating hospital,
having an ovary and not having a malignant tumour were eligible.
Institutional review boards approved the study protocols.
BOT cases were diagnosed in 1992 and 1993. A uniform
pathology review determined eligibility and histologic classifica-
tion (Russell and Bannatyne, 1989). Controls, frequency-matched
to the expected case distribution by 10-year age group and
hospital, were identified using Waksberg’s random digit dialing
(RDD) method (Waksberg, 1978; Hartge et al, 1984). Participation
rates among the cases and controls were 80.7% (n = 746) and
71.4% (n = 404), respectively. RDD screener response rate was
84.9%.
A structured questionnaire was administered. A 127-item
Willett food frequency questionnaire (FFQ) (Willett, 1990) about
usual dietary intake during the 12 to 24 months before interview
was self-completed by 90% (n = 673) of the cases and 87%
(n = 352) of the controls (Britton et al, 2000). Primary lactose
foods included skim or low-fat milk, whole milk, cream, sour
cream, sherbet or ice milk, ice cream, yogurt, cottage or ricotta
cheese, cream cheese, and other cheeses such as American or
cheddar cheese.
Median lactose intakes were compared by the Wilcoxon test
(Conover, 1980). Unconditional logistic regression produced
adjusted odds ratios (ORs) and 95% confidence intervals (CIs)
(Hosmer and Lemeshow, 1989). Controls were compared to all
cases and to the more common histologic sub-types: endo-
metriomas, serious adenomas and teratomas.
Lactose (grams per day) was considered as a continuous and
categorical variable (classified into quartiles). The residual
nutrient method was used for the latter (Willett et al. 1997). Foods
were divided into three categories according to the control
frequency distribution. In the models, categorical variables were
represented as indicator variables and adjustment was made for
age (<25/25–34/35–44/45–54/55–64/65+ years), hospital (seven
categories), total energy (kilocalories per day), and body mass
index (BMI: weight in kilograms/height in metres squared) for the
year prior to interview. When dietary fat and non-dietary factors
were considered as confounders, estimates were unaffected thus
subsequent models omitted these factors. To assess trends, quartile
levels or indicator variable scores were entered in models as
ordinal variables.
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After exclusion of 1% of cases and controls with extreme
energy intake (Howe et al, 1990; Hunter et al, 1996) 668 case
women and 347 control women remained. Women could have
multiple tumours of differing histology as a result the cases were
diagnosed with 717 BOTs: 172 serous, 60 mucinous, 280
endometrioid, and 8 Brenner tumours, as well as 165 teratomas
and 32 fibroma-thecomas. All women (Westhoff et al, 2000) and
those providing dietary information (Britton et al, 2000) had
similar distributions of demographic and other characteristics. In
general, controls were significantly more likely than cases to be
parous and to have a non-private or no health care provider, a
possible indicator of less diagnosis opportunity. Cases were non-
significantly more likely to be white, never OC users and have
larger BMI. The mean case age of 42.2 years (standard deviation
(SD) = 11.9) was slightly older than the mean control age of 41.5
years (SD = 12.5) (P = 0.4).
All cases combined and each histologic type, except endo-
metriomas, had non-significantly higher median lactose intakes
than controls (data not shown). There was no evidence of an
association or a dose–response relation between lactose intake and
BOTs or any of the histologic sub-types (Table 1). Continuous
lactose measures yielded similar findings; the ORs and 95% CIs
per 10 grams of lactose were 0.90 (0.76–1.06), 0.89 (0.65–1.21),
0.96 (0.80–1.16), 1.07 (0.89–1.27), and 0.97 (0.85–1.10), for
endometriomas, mucinous adenomas, adenomas, teratomas, and
all BOTs combined, respectively.
Only whole milk was associated with BOTs (Table 2). A
significant inverse relation was observed for all BOTs combined
and for teratoma tumours, while a borderline significant inverse
association was noted for tumours. Though these tests are indica-
tive of an inverse trend, the observed association for the middle
category of whole milk intake was either the same as or stronger
than that observed for the highest category of intake. There were
no other statistically significant associations or dose–response
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Table 1 Odds ratios and 95% confidence intervals for benign ovarian tumours, according to lactose intake as categorized by quartiles, among 1015 women in
the New York Metropolitan Area, 1992–1993
Controls Endometriomab Mucinous adenoma Serous adenoma Teratomab All casesb
Exposure (no.)a (no.) ORa,c 95% CIa (no.) ORc 95% CI (no.) ORc 95% Cl (no.) ORC 95% CI (no.) ORc 95% CI
Quartiles of lactose
intake (grams)
Q1 (≤ 5.58) 86 72 1.00 15 1.00 51 1.00 38 1.00 174 1.00
Q2 (5.59–10.42) 87 77 1.11 0.69–1.79 14 0.97 0.41–2.28 30 0.61 0.34–1.10 36 1.01 0.56–1.81 161 0.93 0.63–1.36
Q3 (10.43–17.11) 88 74 1.06 0.66–1.70 20 1.37 0.62–3.02 51 1.08 0.63–1.83 50 1.37 0.79–2.38 185 1.04  0.71–1.52
Q4 (>17.11) 86 57 0.77 0.48–1.26 11 0.75 0.31–1.79 40 0.78 0.45–1.35 41 1.05 0.61–1.83 148 0.82 0.57–1.20
P for trend 0.31 0.77 0.82 0.60 0.46
ano., number of subjects; OR, Odds ratio; CI, Confidence interval. bOne woman with a teratoma and one with an endometrioma with missing information on
body mass index (weight in kilograms/height in metres squared) were excluded from the logistic models. cAdjusted for age, hospital, total caloric intake, and
body mass index for the year prior to interview.
Table 2 Odds ratios and 95% confidence intervals for benign ovarian tumours in relation to lactose-food items, among 1015 women in the New York
Metropolitan Area, 1992–1993
Controls Endometriomab Serous adenoma Teratomab All casesb
Exposure (no.)a (no.) ORa,c 95% CIa (no.) ORc 95% Cl (no.) ORc 95% CI (no.) ORc 95% CI
Whole milk (8 oz or 236.8 ml)a
Never or <1/month 191 168 1.00 115 1.00 112 1.00 429 1.00
1/month–≤ 1/week 75 58 0.81 0.54–1.24 20 0.51 0.29–0.91 23 0.48 0.28–0.83 112 0.68 0.48–0.95
2+/week 68 47 0.82 0.52–1.28 24 0.69 0.39–1.20 26 0.59 0.34–1.01 102 0.69 0.48–0.99
Not ascertained 13 7 13 4 25
P for trend 0.29 0.07 0.01 0.02
Skim/low-fat milk (8 oz or 236.8 ml)
Never or <1/month 132 90 1.00 61 1.00 50 1.00 224 1.00
1/month–≤ 1/week 57 48 1.26 0.77–2.06 26 0.99 0.55–1.78 28 1.28 0.72–2.28 102 1.03 0.69–1.53
2+/week 152 137 1.25 0.86–1.81 79 1.13 0.74–1.75 84 1.43 0.92–2.22 328 1.21 0.90–1.63
Not ascertained 6 5 6 3 14
P for trend 0.26 0.56 0.11 0.20
Yogurt (1 c or 226.8 g)a
Never or <1/month 116 94 1.00 51 1.00 60 1.00 222 1.00
1/month–≤ 1/week 126 120 1.15 0.79–1.70 64 1.25 0.77–2.01 60 0.89 0.56–1.39 262 1.08 0.79–1.48
2+/week 101 65 0.84 0.54–1.30 52 1.20 0.73–1.98 44 0.79 0.49–1.29 172 0.86 0.61–1.21
Not ascertained 4 1 5 1 12
P for trend 0.52 0.48 0.35 0.44
ano., number of subjects; OR, odds ratio; CI, confidence interval; ml, millilitres; g, grams; oz, ounces; c, cups. bOne woman with a teratoma and one with an
endometrioma with missing information on body mass index (weight in kilograms/height in metres squared) were excluded from the logistic models. cAdjusted
for age, hospital, total caloric intake, and body mass index for the year prior to interview.1554 JA Britton et al
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relations for BOTs combined or for the individual histologic sub-
types and consumption of any other lactose foods (selected items
shown in Table 2).
DISCUSSION
In this study, whole milk was the only item significantly
associated with BOTs for which estimates were below the null.
Adjustment for total and types of dietary fat as well as lactose did
not change the association. Thus, our results do not support an
increased BOT risk in relation to the lactose or dietary fat
component of dairy products. This agrees with our earlier finding
of no relation between BOTs and saturated fat (Britton et al, 2000).
If BOTs share a common aetiology with, or are precursors of
malignant tumours, then the suggestion that either lactose or high-
fat dairy products (Mettlin and Piver, 1990) increase ovarian
cancer risk is not supported by this study. Our null lactose findings
are consistent with studies examining borderline (Risch et al,
1996) or malignant ovarian (Engle et al, 1991; Risch et al, 1994a;
Herrinton et al, 1995; Mink et al, 1996; Webb et al, 1998) tumours,
but contrast the findings of an elevated ovarian cancer risk in
relation to lactose intake (Cramer et al, 1989) or in relation to the
lactose to transferase ratio (Cramer et al, 1989). Lactose consump-
tion relative to metabolic capability may be a more relevant
measure of galactose exposure but information on transferase
activity or lactose tolerance was not available. Finally, we found a
reduced BOT risk associated with higher whole milk consumption.
Studies of ovarian cancer risk and either whole milk (Cramer et al,
1984, 1989; Mettlin and Piver, 1990; Ursin et al, 1990; Risch et al,
1994a; Webb et al, 1998; Kushi et al, 1999) or dietary fat (Byers
et al, 1983; Shu et al, 1989; Slattery et al, 1989; Tzonou
et al, 1993; Rische et al, 1994b; Mink et al, 1996; Webb et al,
1998; Kushi et al, 1999) consumption have inconsistent findings,
generally reporting no association or an elevated risk.
Participants in health-related studies might be more health
conscious and therefore more likely to consume or report low-fat
foods. This, coupled with the lower control response rate, could
result in selection bias. Or, cases may be more motivated to
provide truthful responses than controls, resulting in recall bias.
These biases would result in an underestimation of low-fat, but an
overestimation of high-fat, food associations. In light of the null
findings, it is hard to conceive that these biases are selectively
affecting low-fat food associations. Lactose findings should be
unaffected because the lactose and fat content of foods are
independent.
We assessed commonly eaten major and minor lactose sources
enabling us to rank participants’ lactose exposure. The foods
assessed were similar to the short list of items examined in a study
reporting a high correlation (r = 0.96) between lactose estimated
using 34 versus 7 lactose foods (Cooper et al, 1995). Among
controls the expected ethnic/racial variation in lactose intake was
observed (Scrimshaw and Murray, 1988). These findings, together
with the similar mean lactose intakes for our white controls and
those in another study (Cramer et al, 1989), lend credence to our
lactose measure.
Overall the study’s findings do not support an elevated BOT risk
in relation to lactose and are consistent with the results of most of
the ovarian cancer studies (Engle et al, 1991; Risch
et al, 1994a, 1996; Herrinton et al, 1995; Mink et al, 1996; Webb et
al, 1998). The failure to detect an association might reflect a lack
of power particularly in the histologic sub-type analyses. Finally,
the reduction in BOT risk for greater whole milk intake could be a
chance finding given the multiple comparisons made.
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